Physician profile
Emma Clelland
NPI 1437908316
$611.10
in general payments reported to CMS, 2019-2025
13 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $340 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $541 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $541.11 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $106.23 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $91.33 | 2024-2025 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $87.87 | 2024-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $53.85 | 2024 | |
| Novo Nordisk INC | $50.14 | 2025 | Wegovy, Rybelsus, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.64 | 2024-2025 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $35.23 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $34.80 | 2025 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.89 | 2025 | Jardiance |
| Pfizer INC. | $27.13 | 2024 | |
| Philips North America LLC | $21.50 | 2025 | Mcot |
| Novartis Pharmaceuticals Corporation | $15.69 | 2025 | |
| Cashflow Solutions, LLC | $14.80 | 2024 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Clelland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.